Literature DB >> 24669302

Role of modern radiation therapy in early stage Hodgkin's lymphoma: A young radiation oncologists' perspective.

Andrea Riccardo Filippi1, Pierfrancesco Franco2, Patrizia Ciammella3.   

Abstract

The role of radiotherapy is well established in combined modality programs for early stage Hodgkin's lymphoma, but still debated with regards to late toxicity issues. Modern radiotherapy prescribing attitudes include lower doses and smaller fields, together with the implementation of sophisticated and dedicated delivery techniques. Aim of this review is to briefly discuss the current role of radiotherapy in this field and the potential future developments. Major trials conducted in recent years in early stage Hodgkin's lymphoma are critically reviewed and discussed with a focus on radiotherapy-related issues and with an attention to current treatment options by a "young" radiation oncologists' perspective.

Entities:  

Keywords:  Combined modality therapy; Hodgkin's lymphoma; Radiotherapy

Year:  2012        PMID： 24669302      PMCID： PMC3885894          DOI： 10.1016/j.rpor.2012.05.003

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN： 1507-1367


  19 in total

1.  Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease.

Authors:  David J Straus; Carol S Portlock; Jing Qin; Jane Myers; Andrew D Zelenetz; Craig Moskowitz; Ariela Noy; André Goy; Joachim Yahalom
Journal:  Blood       Date:  2004-08-17       Impact factor: 22.113

2.  Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy.

Authors:  Julia Koeck; Yasser Abo-Madyan; Frank Lohr; Florian Stieler; Jan Kriz; Rolf-Peter Mueller; Frederik Wenz; Hans Theodor Eich
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-11-11       Impact factor: 7.038

3.  Chemotherapy alone for early-stage Hodgkin's lymphoma.

Authors:  David J Straus
Journal:  N Engl J Med       Date:  2011-12-11       Impact factor: 91.245

4.  Current role and future developments of radiotherapy in early-stage favourable Hodgkin's lymphoma.

Authors:  Hans Theodor Eich; Rolf-Peter Müller
Journal:  Strahlenther Onkol       Date:  2007-12       Impact factor: 3.621

5.  Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes.

Authors:  Marie L De Bruin; Judith Sparidans; Mars B van't Veer; Evert M Noordijk; Marieke W J Louwman; Josée M Zijlstra; Hendrik van den Berg; Nicola S Russell; Annegien Broeks; Margreet H A Baaijens; Berthe M P Aleman; Flora E van Leeuwen
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

6.  Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma.

Authors:  Amaury Paumier; Mithra Ghalibafian; Anne Beaudre; Ivaldo Ferreira; Charlotte Pichenot; Taha Messai; Nathalie Athalie Lessard; Dimitri Lefkopoulos; Theodore Girinsky
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-05-01       Impact factor: 7.038

7.  Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone.

Authors:  E Dühmke; J Franklin; M Pfreundschuh; S Sehlen; N Willich; U Rühl; R P Müller; P Lukas; A Atzinger; U Paulus; B Lathan; U Rüffer; M Sieber; J Wolf; A Engert; A Georgii; S Staar; R Herrmann; M Beykirch; H Kirchner; A Emminger; R Greil; E Fritsch; P Koch; A Drochtert; O Brosteanu; D Hasenclever; M Loeffler; V Diehl
Journal:  J Clin Oncol       Date:  2001-06-01       Impact factor: 44.544

8.  Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.

Authors:  Hans Theodor Eich; Volker Diehl; Helen Görgen; Thomas Pabst; Jana Markova; Jürgen Debus; Anthony Ho; Bernd Dörken; Andreas Rank; Anca-Ligia Grosu; Thomas Wiegel; Johann Hinrich Karstens; Richard Greil; Normann Willich; Heinz Schmidberger; Hartmut Döhner; Peter Borchmann; Hans-Konrad Müller-Hermelink; Rolf-Peter Müller; Andreas Engert
Journal:  J Clin Oncol       Date:  2010-08-16       Impact factor: 44.544

Review 9.  Cyberknife: A double edged sword?

Authors:  Bindhu Joseph; Sanjay S Supe; Aruna Ramachandra
Journal:  Rep Pract Oncol Radiother       Date:  2010-07-06

10.  Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.

Authors:  Andreas Engert; Jeremy Franklin; Hans Theodor Eich; Corinne Brillant; Susanne Sehlen; Claudio Cartoni; Richard Herrmann; Michael Pfreundschuh; Markus Sieber; Hans Tesch; Astrid Franke; Peter Koch; Maike de Wit; Ursula Paulus; Dirk Hasenclever; Markus Loeffler; Rolf-Peter Müller; Hans Konrad Müller-Hermelink; Eckhart Dühmke; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-07-02       Impact factor: 44.544
View more
  3 in total

Review 1.  Total skin electron beam (TSEB) therapy in pediatric patients: A review of the literature.

Authors:  Małgorzata Skórska
Journal:  Rep Pract Oncol Radiother       Date:  2013-07-19

2.  Radiotherapy for patients with stage IV classical Hodgkin lymphoma: a propensity-matched analysis of the surveillance, epidemiology, and end results database.

Authors:  Shijie Wang; Mingfang Jia; Jianglong Han; Rui Zhang; Kejie Huang; Ping Li; Qin Li; Yunfeng Qiao; Qibin Song; Zhenming Fu
Journal:  Cancer Biol Ther       Date:  2020-08-23       Impact factor: 4.742

Review 3.  Nonclonal Chromosome Aberrations and Genome Chaos in Somatic and Germ Cells from Patients and Survivors of Hodgkin Lymphoma.

Authors:  Sara Frias; Sandra Ramos; Consuelo Salas; Bertha Molina; Silvia Sánchez; Roberto Rivera-Luna
Journal:  Genes (Basel)       Date:  2019-01-10       Impact factor: 4.096
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.